Traditional drug discovery takes a long time and costs a lot. Developing one new medicine can take 10 to 15 years. It involves many steps, like finding a target, testing compounds, running clinical trials, and getting approval from regulators. Usually, making a new drug costs about $1 billion. Most drug ideas don\u2019t work out\u2014around 90% fail in early or clinical trials. AI offers ways to make this process faster and cheaper while helping drugs succeed more often.<\/p>\n
AI tools like machine learning (ML) and deep learning (DL) help researchers study huge amounts of data that people cannot handle easily. This data includes information about chemicals, genes, trial results, and molecule structures. AI can find hidden patterns, predict how new drug molecules might act, and guess if they will be safe and effective.<\/p>\n
For example, AI systems look at how molecules and patient data interact to find new drug targets much faster than usual lab work. They can also improve lead compounds by guessing their qualities like toxicity without too much trial and error. Generative AI models can even create new drug molecules on the computer, letting companies test options beyond existing ones.<\/p>\n
One big example is DeepMind\u2019s AlphaFold, which uses AI to predict the 3D shapes of proteins. It predicted the structures of more than 330,000 proteins, including all human ones, in just months. This helps scientists understand diseases better and design drugs more precisely.<\/p>\n
These advances help design drugs more quickly, make research smoother, and shorten the time it takes to bring new medicines to patients.<\/p>\n
These steps show that AI is now part of real world drug research and is accepted by regulators. More than 150 small-molecule drugs are being developed with AI methods. Over 15 of these are already in clinical trials. Morgan Stanley says AI could help approve 50 more new therapies in the next 10 years, making a market worth over $50 billion.<\/p>\n
Big drug companies like Johnson & Johnson, AbbVie, Eli Lilly, Pfizer, and Roche use AI to speed up drug discovery. Johnson & Johnson uses AI to find new drug targets and improve molecule searches. They also use AI to help recruit patients for clinical trials. AbbVie\u2019s R&D Convergence Hub (ARCH) combines different data and AI to speed research and create patient-specific treatments.<\/p>\n
Partnerships between drug and tech companies add computing power and help train AI models. Roche works with NVIDIA and Amazon Web Services (AWS) to handle large data sets needed for drug research, using powerful computers for machine learning tasks.<\/p>\n
<\/p>\n